Anti-bevacizumab idiotype antibody vaccination is effective in inducing vascular endothelial growth factor-binding response, impairing tumor outgrowth

Página do item simplificado
dc.citation.issue4
dc.citation.volume107
dc.contributor.authorSanches, Jessica de Souza [UNIFESP]
dc.contributor.authorAguiar, Rodrigo Barbosa de [UNIFESP]
dc.contributor.authorParise, Carolina Bellini [UNIFESP]
dc.contributor.authorSuzuki, Juliana Mayumi [UNIFESP]
dc.contributor.authorChammas, Roger [UNIFESP]
dc.contributor.authorMoraes, Jane Zveiter de [UNIFESP]
dc.coverageHoboken
dc.date.accessioned2020-07-22T13:23:12Z
dc.date.available2020-07-22T13:23:12Z
dc.date.issued2016
dc.description.abstractTumors require blood supply and, to overcome this restriction, induce angiogenesis. Vascular endothelial growth factor (VEGF) plays an important role in this process, which explains the great number of antiangiogenic therapies targeting VEGF. The research and development of targeted therapy has led to the approval of bevacizumab, a humanized anti-VEGF monoclonal antibody (mAb), in clinical settings. However, side effects have been reported, usually as a consequence of bolus-dose administration of the antibody. This limitation could be circumvented through the use of anti-idiotype (Id) antibodies. In the present study, we evaluated the efficacy of an active VEGF-binding immune response generated by an anti-bevacizumab idiotype mAb, 10.D7. The 10.D7 anti-Id mAb vaccination led to detectable levels of VEGF-binding anti-anti-Id antibodies. In order to examine whether this humoral immune response could have implications for tumor development, 10.D7-immunized mice were challenged with B16-F10 tumor cells. Mice immunized with 10.D7 anti-Id mAb revealed reduced tumor growth when compared to control groups. Histological analyses of tumor sections from 10.D7-immunized mice showed increased necrotic areas, decreased CD31-positive vascular density and reduced CD68-positive cell infiltration. Our results encourage further therapeutic studies, particularly if one considers that the anti-Id therapeutic vaccination maintains stable levels of VEGF-binding antibodies, which might be useful in the control of tumor relapse.en
dc.description.affiliationUniv Fed Sao Paulo, Escola Paulista Med, Dept Biophys, Rua Botucatu 862, BR-04023062 Sao Paulo, Brazil
dc.description.affiliationUniv Sao Paulo, Fac Med, Dept Radiol, Sao Paulo, Brazil
dc.description.affiliationUnifespUniv Fed Sao Paulo, Escola Paulista Med, Dept Biophys, Rua Botucatu 862, BR-04023062 Sao Paulo, Brazil
dc.description.sourceWeb of Science
dc.description.sponsorshipCoordenacao de Aperfeicoamento de Pessoal de Nivel Superior
dc.description.sponsorshipFundacao de Apoio a Pesquisa do Estado de Sao Paulo
dc.format.extent551-555
dc.identifierhttp://dx.doi.org/10.1111/cas.12903
dc.identifier.citationCancer Science. Hoboken, v. 107, n. 4, p. 551-555, 2016.
dc.identifier.doi10.1111/cas.12903
dc.identifier.fileWOS000377906400023.pdf
dc.identifier.issn1349-7006
dc.identifier.urihttps://repositorio.unifesp.br/handle/11600/56091
dc.identifier.wosWOS:000377906400023
dc.language.isoeng
dc.publisherWiley
dc.relation.ispartofCancer Science
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectAngiogenesisen
dc.subjectidiotypeen
dc.subjectmonoclonal antibodyen
dc.subjectvaccinationen
dc.subjectvascular endothelial growth factoren
dc.titleAnti-bevacizumab idiotype antibody vaccination is effective in inducing vascular endothelial growth factor-binding response, impairing tumor outgrowthen
dc.typeinfo:eu-repo/semantics/article
Arquivos
Pacote Original
Agora exibindo 1 - 1 de 1
Imagem de Miniatura
Nome:
WOS000377906400023.pdf
Tamanho:
2.85 MB
Formato:
Adobe Portable Document Format
Descrição:
Baixar
Coleções
EPM - Artigos